History of cancer and induced menopause: Help – cannot be reconciled

Approximately one in five men or women develops some form of malignant neoplasm (MN) in their lifetimes. Around one in nine men and one in 12 women die from cancer. Ten major types of cancer comprise two-thirds of all new cases of cancer. Now, we can witness a change from impersonal treatment efficacy assessment to a personalized approach, including an analysis of cancer patient’s QoL, his/her age, comorbidity, stage, and immunohistochemical and molecular genetic characteristics of the tumour process. Despite revolutionary advancements in understanding of the molecular biology of tumours, innovative techniques in the development of cytoreductive and anti-tumour treatments, cancer remains one of the most serious health challenges and a leading cause of death worldwide. Challenges in early diagnosis of cancer, the absence of clear markers for tissue "readiness" for tumour growth, the inadequacy of the principle of anti-tumour therapy personalization and a number of other issues do not allow to get out of the vicious circle. The epidemiology of oncological conditions is characterized by gender differences. Breast, lung, and colorectal cancers are the most commonly reported cancer in women. Modern advances in oncology have led to an increase in survival rates in cancer female patients. However, anti-tumour therapy (AT) is characterized by a diverse array of toxic effects on organs and systems. In women, AT is often complicated by premature ovarian failure (POF). Therefore, a significant percentage of women need to u se menopausal hormone therapy (MHT) after successful completion of cancer treatment. This article presents the results of the search for information about the acceptability of MHT for female patients after treatment of non-gynecological cancers, as well as alternative therapy options for menopausal disorders.

1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer; 2024. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf.

2. Massarotti C, Scaruffi P, Lambertini M, Remorgida V, Del Mastro L, Anserini P. State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. Cancer Treat Rev. 2017;57:50–57. https://doi.org/10.1016/j.ctrv.2017.04.009.

3. Hickey M, Basu P, Sassarini J, Stegmann ME, Weiderpass E, Nakawala Chilowa K et al. Managing menopause after cancer. Lancet. 2024;403(10430):984–996. https://doi.org/10.1016/S0140-6736(23)02802-7.

4. Dobrokhotova YuE, Lysenko MA, Grabovsky VM, Shevchenko NA, Grashchenko IM. Fertility preservation problem in oncohematological patients of reproductive age. Russian Journal of Woman and Child Health. 2023;6(4):362–367. (In Russ.) Available at: https://www.rmj.ru/articles/onkologiya/Problema_sohraneniya_fertilynosti_u_onkogematologicheskih_pacientok_reproduktivnogo_vozrasta/?ysclid=m9l0qbjyf5523580479#.

5. Каприн АД, Старинский ВВ, Петрова ГВ (ред.). Состояние онкологической помощи населению России в 2018 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии»; 2019. 236 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2020/09/sostoyanie_2018.pdf.

6. Anderson RA, Cameron D, Clatot F, Demeestere I, Lambertini M, Nelson SM, Peccatori F. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update. 2022;28(3):417–434. https://doi.org/10.1093/humupd/dmac004.

7. Leone T. Women’s mid-life health in Low and Middle Income Countries: A comparative analysis of the timing and speed of health deterioration in six countries. SSM Popul Health. 2018;7:100341. https://doi.org/10.1016/j.ssmph.2018.100341.

8. Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB et al. Fertility preservation and post-treatment pregnancies in postpubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1664–1678. https://doi.org/10.1016/j.annonc.2020.09.006.

9. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. https://doi.org/10.1097/GME.0000000000002028.

10. Iakushevskaia OV, Iureneva SV, Protasova AE, Khabas GN, Ashrafian LA. Menopausal hormone therapy and non-gynecologic cancer (part II). Gynecology. 2019;21(1):86–90. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/30140.

11. Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I et al. Evidence-based approaches for the management of sideeffects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–e313. https://doi.org/10.1016/S1470-2045(20)30666-5.

12. Taylor A, Clement K, Hillard T, Sassarini J, Ratnavelu N, Baker-Rand H et al. British Gynaecological Cancer Society and British Menopause Society guidelines: Management of menopausal symptoms following treatment of gynaecological cancer. Post Reprod Health. 2024;30(4):256–279. https://doi.org/10.1177/20533691241286666.

13. Yang X, Wang C, He X, Wei J, Wang Y, Li X, Xu LP. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric. 2017;20(3):268–273. https://doi.org/10.1080/13697137.2017.1309382.

14. MacKie RM, Bray CA. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer. 2004;90(4):770–772. https://doi.org/10.1038/sj.bjc.6601595.

15. Chan JA, Meyerhardt JA, Chan AT, Giovannucci EL, Colditz GA, Fuchs CS. Hormone replacement therapy and survival after colorectal cancer diagnosis. J Clin Oncol. 2006;24(36):5680–5686. https://doi.org/10.1200/JCO.2006.08.0580.

16. Ji J, Sundquist J, Sundquist K. Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: A populationbased study in Sweden. Int J Cancer. 2018;142(10):2003–2010. https://doi.org/10.1002/ijc.31228.

17. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D et al. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017;15(11):1791–1799. https://doi.org/10.1016/j.cgh.2017.05.036.

18. Brennan A, Rees M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101575. https://doi.org/10.1016/j.beem.2021.101575.

19. Zhang X, Du Y, Tan X, Wang H, Li Y, Zhang Z, Wang A. The Relationship Between Hormone Replacement Therapy and Risk of Kidney Cancer in Women: A Meta-Analysis. Cancer Control. 2020;27(2):1073274820930194. https://doi.org/10.1177/1073274820930194.

20. Clague J, Reynolds P, Henderson KD, Sullivan-Halley J, Ma H, Lacey JV Jr et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study. PLoS ONE. 2014;9(7):e103735. https://doi.org/10.1371/journal.pone.0103735.

21. Katcoff H, Wenzlaff AS, Schwartz AG. Survival in women with NSCLC: the role of reproductive history and hormone use. J Thorac Oncol. 2014;9(3):355–361. https://doi.org/10.1097/JTO.0000000000000077.

22. Ganti AK, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006;24(1):59–63. https://doi.org/10.1200/JCO.2005.02.9827.

23. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009;374(9697):1243–1251. https://doi.org/10.1016/S0140-6736(09)61526-9.

24. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.

25. Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914.

26. Lee YJ, Kim JS, Jo JC, Kim Y, Im HS, Kim H et al. Risk factors of menopause after allogeneic hematopoietic cell transplantation in premenopausal adult women. Eur J Haematol. 2023;111(3):449–457. https://doi.org/10.1111/ejh.14027.

27. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors – Review of the Literature. Pathol Oncol Res. 2020;26(1):63–78. https://doi.org/10.1007/s12253-018-00569-x.

28. Botteri E, Støer NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind et al. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer. 2017;141(9):1763–1770. https://doi.org/10.1002/ijc.30878.

29. Marzagalli M, Casati L, Moretti RM, Montagnani Marelli M, Limonta P. Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS ONE. 2015;10(7):e0134396. https://doi.org/10.1371/journal.pone.0134396.

30. Yakushevskaya OV, Yureneva SV, Protasova AE, Khabas GN, Ashrafyan LA. Menopausal hormone therapy and nongynecological cancer (neoplasms of the digestive organs). Akusherstvo i Ginekologiya: Novosti, Mneniya, Obuchenie. 2019;7(1):52–60. (In Russ.) https://doi.org/10.24411/2303-9698-2019-11007.

31. Kim SM, Min BH, Lee J, An JY, Lee JH, Sohn TS et al. Protective Effects of Female Reproductive Factors on Lauren Intestinal-Type Gastric Adenocarcinoma. Yonsei Med J. 2018;59(1):28–34. https://doi.org/10.3349/ymj.2018.59.1.28.

32. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):20–38. https://doi.org/10.1158/1055-9965.EPI-11-0834.

33. Hogan AM, Collins D, Baird AW, Winter DC. Estrogen and gastrointestinal malignancy. Mol Cell Endocrinol. 2009;307(1-2):19–24. https://doi.org/10.1016/j.mce.2009.03.016.

34. Hoekman EJ, Broeders EABJ, Louwe LA, Nout RA, Jansen FW, de Kroon CD. Ovarian function after ovarian transposition and additional pelvic radiotherapy: A systematic review. Eur J Surg Oncol. 2019;45(8):1328–1340. https://doi.org/10.1016/j.ejso.2019.02.017.

35. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1(1):CD004143. https://doi.org/10.1002/14651858.CD004143.pub5.

36. Guo-Chao Zhong, Yan Liu, Nan Chen. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies. Hum Reprod Update. 2016;23(1):126–138. https://doi.org/10.1093/humupd/dmw037.

37. Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer. 2016;2(2):127–137. https://doi.org/10.3233/BLC-160052.

38. Hsu LH, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci. 2017;18(8):1713. https://doi.org/10.3390/ijms18081713.

39. Li W, Lin X, Wang R, Wang F, Xie S, Tse LA. Hormone therapy and lung cancer mortality in women: Systematic review and meta-analysis. Steroids. 2017;118:47–54. https://doi.org/10.1016/j.steroids.2016.12.005.

40. Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U et al. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Med. 2021;18(8):e1003731. https://doi.org/10.1371/journal.pmed.1003731.

41. Mendoza N, Ramírez I, de la Viuda E, Coronado P, Baquedano L, Llaneza P et al. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group. Maturitas. 2022;166:65–85. https://doi.org/10.1016/j.maturitas.2022.08.008.

42. Hickey M, Szabo RA, Hunter MS. Non-hormonal treatments for menopausal symptoms. BMJ. 2017;359:j5101. https://doi.org/10.1136/bmj.j5101.

43. Sarri G, Pedder H, Dias S, Guo Y, Lumsden MA. Vasomotor symptoms resulting from natural menopause: a systematic review and network metaanalysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG. 2017;124(10):1514–1523. https://doi.org/10.1111/1471-0528.14619.

44. Averkova VG, Yakushevskaya OV. Alternative and complementary correction of menopausal disorders. Meditsinskiy Sovet. 2022;16(16):124–129. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-16-124-129.

45. Chen LR, Ko NY, Chen KH. Isoflavone Supplements for Menopausal Women: A Systematic Review. Nutrients. 2019;11(11):2649. https://doi.org/10.3390/nu11112649.

46. Bonga KN, Mishra A, Maiti R, Padhy BM, Meher BR, Srinivasan A. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis. Obstet Gynecol. 2024;143(3):393–402. https://doi.org/10.1097/AOG.0000000000005508.

47. Hipkiss AR, Baye E, de Courten B. Carnosine and the processes of ageing. Maturitas. 2016;93:28–33. https://doi.org/10.1016/j.maturitas.2016.06.002.

48. Berti Zanella P, Donner Alves F, Guerini de Souza C. Effects of beta-alanine supplementation on performance and muscle fatigue in athletes and nonathletes of different sports: a systematic review. J Sports Med Phys Fitness. 2017;57(9):1132–1141. https://doi.org/10.23736/S0022-4707.16.06582-8.

49. Andreeva E, Tkeshelashvili B. Women dealing with hot flushes: the role of β-alanine. Eur Rev Med Pharmacol Sci. 2020;24(9):5148–5154. https://doi.org/10.26355/eurrev_202005_21209.

50. Tatarova NA, Marzhevskaya AM, Gavrilova NP, Savina LV. Correction of estrogen deficiency states in women with endometriosison the background of therapygonadtropin-releasing hormone. Gynecology. 2013;15(6):28–31. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/28261.